CAPhO Connections Podcast Episode 16 Available

CAPhO Connections Podcast Series keeps the oncology pharmacy community informed on matters affecting you and updated on CAPhO’s news related to education, awards, advocacy, and research.

Episode 16: Treating AML in the Elderly/Unfit Population - how do we manage the treatment regimen we always wanted?

AML treatment options have exploded in the past 10+ years including the approval of different regimens in the non-intensive management of the disease. This podcast will review current practices and considerations for infection prevention for patients treated with myelosuppressive AML regimens.

Learning Objectives:

  • Describe the epidemiology, pathophysiology, and prognostic factors in the non-intensive management of AML
  • Review the Canadian Landscape with a focus on current and emerging treatment options for the non-intensive management of AML
  • Discuss current antimicrobial prophylaxis practices at different North American Oncology Centres
  • Review current evidence for infection prophylaxis and drug interaction management in this population
  • Review monitoring, following up and supportive care considerations for the Canadian Pharmacist


About the Author: Jonathan Stevens

Jonathan Stevens is a graduate from the Memorial University School of Pharmacy completing his BScPharm in 2014 and PharmD in 2023. He also completed a hospital pharmacy residency at the Saint John Regional Hospital in 2015. He is an Oncology Pharmacy Program Manager and holds a clinical practice in outpatient hematology focusing on patient education, monitoring and toxicity management.



Information and additional resources mentioned during this episode of the podcast:

  • Statistics Canada. Number and rates of new cases of primary cancer, by cancer type, age group and sex. Available online at:
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Acute Myeloid Leukemia. Version 6.2023 – October 24, 2023. Available online at
  • Sekeres M, Guyatt G, Abel G, Alibhai S, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv (2020); 4(15):3528-3549.
  • Dinard C, Jonas B, Pullarkat V, Thirman M, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Eng J Med (2020); 383:617-629.
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Prevention and Treatment of Cancer-Related Infections. Version 1.2023 – June 28, 2023. Available online at
  • Maschmeyer G, Bullinger L, Garcia-Vidal C, Herbrecht R, et al. Infectious Complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia (2022); 36(5):1215-1226.